Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care.
Moreno-Olmedo E., Owczarczyk K., Chadwick E., Dickinson P., Duffton A., Jones B., Good JS., McDonald F., Murray LJ., Rackley T., Robinson M., Sinclair J., Strawson-Smith T., Tree A., Tsang YM., Zarkar A., Dean C., Díez P., Williams M., Andratschke N., Muirhead R.
Stereotactic ablative body radiotherapy (SABR) is routinely used for the management of oligometastatic disease. Increasingly, there is overlap of targets or organs at risk with previous radiotherapy fields. As substantial variation in delivery of clinical practice exists, the UK SABR Consortium worked with a collaborative national group to develop pelvic SABR re-irradiation consensus guidelines. The scope of the guidance includes patient selection criteria, pre-treatment considerations, delineation guidelines, dose prescription, calculations of cumulative dose constraints, and optimal planning technique. This guidance is part of an ongoing national prospective audit in collaboration with the Royal College of Radiologists and EORTC ReCare.